CINACALCET HYDROCHLORIDE generics — when can they launch?
CINACALCET HYDROCHLORIDE (CINACALCET HYDROCHLORIDE) · · 6 active US patents · 0 expired
Where CINACALCET HYDROCHLORIDE sits in the generic timeline
All listed Orange Book patents for CINACALCET HYDROCHLORIDE have expired. Generic entry is permitted, and ANDA filers can launch without patent infringement risk. Hatch-Waxman exclusivity (NCE/ODE/PED) may still apply if recently approved.
Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.
Patent estate by type — active patents
Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.
- Formulation — 3 patents
- Method of Use — 3 patents
FDA U-codes carved out by CINACALCET HYDROCHLORIDE patents
Method-of-use patents are listed against specific FDA Patent Use Codes ("U-codes") representing carved-out indications. Generics can launch with a label that omits these uses.
| U-code | Description |
|---|---|
U-1098 | (no description) |
Sample patent estate
Showing 6 of 6 active US patents. View full estate on the CINACALCET HYDROCHLORIDE drug page →
-
This patent protects a pharmaceutical composition with a controlled dissolution profile containing a calcium receptor-active compound, such as cinacalcet hydrochloride.USPTO title: Rapid dissolution formulation of a calcium receptor-active compound
-
This patent protects a pharmaceutical composition with a controlled dissolution profile containing a calcium receptor-active compound, such as cinacalcet hydrochloride.USPTO title: Rapid dissolution formulation of a calcium receptor-active compound
-
This patent protects a pharmaceutical composition with a controlled dissolution profile containing a calcium receptor-active compound, such as cinacalcet hydrochloride.USPTO title: Rapid dissolution formulation of a calcium receptor-active compound
-
This patent protects a method of manufacturing a pharmaceutical composition with a controlled dissolution profile for a calcium receptor-active compound.USPTO title: Rapid dissolution formulation of a calcium receptor-active compound
-
This patent protects a method of manufacturing a pharmaceutical composition with a controlled dissolution profile for a calcium receptor-active compound.USPTO title: Rapid dissolution formulation of a calcium receptor-active compound
-
This patent protects a method of manufacturing a pharmaceutical composition with a controlled dissolution profile for a calcium receptor-active compound.USPTO title: Rapid dissolution formulation of a calcium receptor-active compound
Sources
- FDA Orange Book — patents listed against CINACALCET HYDROCHLORIDE (NDA filed 2004)
- CINACALCET HYDROCHLORIDE drug profile — full patent estate, indications, clinical trials, pricing
- Patent cliff 2026 — every drug losing US exclusivity that year
Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.
Get generic entry alerts
Free Pharma CI alerts on CINACALCET HYDROCHLORIDE — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.
Subscribe free →